Matricelf Ltd. (MTLF)
Market Closed
10 Aug, 15:25
TASE TASE Primary 255. 30
ILA -4.6
-1.7699%
10.54B Market Cap
- P/E Ratio
- Div Yield
63,721 Volume
0 Eps
259.9 ILA
Previous Close Want to track MTLF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
MTLF closed today lower at 255.3 ILA, a decrease of -1.7699% from yesterday's close, completing a monthly decrease of -6.5178% or -17.8 ILA. Over the past 12 months, MTLF stock lost -57.45%.
MTLF is not paying dividends to its shareholders.
The last earnings report, released on Jan 16, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Matricelf Ltd. (MTLF) FAQ
What is the stock price today?
The current price is 255.30 ILA.
On which exchange is it traded?
Matricelf Ltd. is listed on TASE.
What is its stock symbol?
The ticker symbol is MTLF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 10.54B.
Has Matricelf Ltd. ever had a stock split?
No, there has never been a stock split.
Matricelf Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Alon Sinai CEO | TASE Exchange | IL0011767915 ISIN |
| Israel Country | 12 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Matricelf Ltd is a pioneering biotechnology firm, established in 2019 and located in Ness Ziona, Israel, that focuses on the groundbreaking development of autologous matrix and cells implants. Through its innovative regenerative medicine platform, it aims to offer healing solutions for a spectrum of medical conditions that have long challenged the healthcare industry. Their work encapsulates a futuristic approach towards medicine, where the integration of technology and biology can lead to significant advancements in how diseases and injuries are treated, potentially altering the course of patient care and recovery.
Products and Services
- Spinal Cord Injuries Treatment: Matricelf is working on a novel approach to treat spinal cord injuries using its regenerative medicine platform. This technology harnesses the power of autologous matrix and cells implants to repair damage and restore function, offering hope to millions suffering from paralysis and related conditions.
- Age-Related Macular Degeneration Therapy: Addressing one of the leading causes of vision loss in older adults, Matricelf’s innovative solution for age-related macular degeneration involves the application of its cutting-edge platform to regenerate damaged tissues in the eye, potentially restoring vision or halting the progression of the disease.
- Parkinson's Disease Management: With the incidence of Parkinson's Disease increasing globally, Matricelf’s therapies aim at mitigating the neurodegenerative progression through the regeneration of neurons and restoration of neural functions, offering a new lease on life for those affected by this debilitating condition.
- Myocardial Infarction Recovery: Heart attacks cause significant cardiac tissue damage, leading to compromised heart function. Matricelf’s regenerative medicine platform presents a novel method to heal the heart by regenerating myocardial tissue, thus improving the recovery outcomes for myocardial infarction patients.
- 3D Organ Printing: Beyond treating diseases, Matricelf is at the forefront of 3D organ printing technology. Their work promises a future where organ shortages are no longer a barrier to transplantation, with the potential for printing organs that are biocompatible and tailored to the individual needs of patients.
Contact Information
Address: Golda Meir 3
Phone: 972 524029178
Website: https://matricelf.com
